Author:
Ikawa Kazuro,Morikawa Norifumi,Ikeda Kayo,Nomura Kenichi,Taniwaki Masafumi,Ohge Hiroki,Sueda Taijiro
Subject
Infectious Diseases,Pharmacology (medical),Microbiology (medical)
Reference25 articles.
1. Significant role of new cephem antibiotics: focused on cefozopran;Kobayashi;Jpn J Antibiot,1997
2. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint;Drusano;Antimicrob Agents Chemother,2001
3. Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa;Tam;Pharmacotherapy,2003
4. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals;Ludwig;Int J Antimicrob Agents,2006
5. Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation;Eagye;Clin Ther,2007
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献